A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7

Human adenovirus types 4 (HAdV4) and 7 (HAdV7) often lead to severe respiratory diseases and occur epidemically in children, adults, immune deficiency patients, and other groups, leading to mild or severe symptoms and even death. However, no licensed adenovirus vaccine has been approved in the marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jingao, Zhang, Youbin, Zhang, Yan, Zhang, Chao, Zhu, Caihong, Xing, Man, Wang, Xiang, Zhou, Dongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477930/
https://www.ncbi.nlm.nih.gov/pubmed/34520320
http://dx.doi.org/10.1080/22221751.2021.1981157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477930/
https://www.ncbi.nlm.nih.gov/pubmed/34520320
http://dx.doi.org/10.1080/22221751.2021.1981157

Ejemplares similares